Investigation of Potential Cardiotoxicity of Anti-PD-1 Immune Checkpoint Inhibitor

Investigation of Potential Cardiotoxicity of Anti-PD-1 Immune Checkpoint Inhibitor

碩士 === 國立成功大學 === 臨床醫學研究所 === 107

Bibliographic Details
Main Authors:	Woan Ting,Tay, 鄭婉婷
Other Authors:	Ping-Yen, Liu
Format:	Others
Language:	en_US
Published:	2019
Online Access:	http://ndltd.ncl.edu.tw/handle/26xgeq

Similar Items

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
by: YU Lin, et al.
Published: (2021-08-01)

Cardiotoxicity and Mechanisms of Immune Checkpoint Inhibitors
by: DONG Shuang, et al.
Published: (2018-11-01)

Cardiotoxicity from immune checkpoint inhibitors
by: Lars Michel, et al.
Published: (2019-12-01)

Managing cardiotoxicity associated with immune checkpoint inhibitors
by: Sireesha Upadhrasta, et al.
Published: (2019-03-01)

Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1
by: Yi-Chi eKong, et al.
Published: (2014-05-01)

Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity
by: Xiaoxiao Guo, et al.
Published: (2020-02-01)

Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies
by: Shirley Xu, et al.
Published: (2021-02-01)

An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors
by: Roberta Esposito, et al.
Published: (2021-05-01)

Gender differences in cardiotoxicities associated with immune checkpoint inhibitor therapy in cancer patients
by: Sheharyar Minhas, et al.
Published: (2020-01-01)

Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients
by: Fan, Q., et al.
Published: (2022)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01)

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
by: Akintunde Akinleye, et al.
Published: (2019-09-01)

Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies)
by: Ruriko Ono, et al.
Published: (2019-07-01)

Inflammatory Biomarkers to Detect Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Lung Cancer Patients
by: Mandar A. Aras, MD, PhD, et al.
Published: (2020-09-01)

Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management
by: Yu-Wen Zhou, et al.
Published: (2019-11-01)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
by: Dongxu Wang, et al.
Published: (2019-04-01)

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS
by: Chenxin Chen, et al.
Published: (2021-02-01)

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
by: Muhammad Zubair Afzal, et al.
Published: (2018-07-01)

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
by: Deirdre Kelly, et al.
Published: (2021-01-01)

PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
by: Pottayil G. Sasikumar, et al.
Published: (2021-06-01)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021-09-01)

The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
by: Lihu Gu, et al.
Published: (2019-06-01)

Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting
by: Melissa Y.Y. Moey, MD, MSc, et al.
Published: (2020-09-01)

PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines
by: Mohammed Safi, et al.
Published: (2021-03-01)

Anti-PD1 checkpoint inhibitor with or without chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma
by: Ting Jin, et al.
Published: (2021-02-01)

Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients
by: Matthias Preusser, et al.
Published: (2021-03-01)

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
by: Jeffrey M. Conroy, et al.
Published: (2019-01-01)

Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer
by: Di ZHANG, et al.
Published: (2019-06-01)

PD-1 Checkpoint Inhibitor Associated Autoimmune Encephalitis
by: Stephanie Schneider, et al.
Published: (2017-05-01)

Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors
by: Luisa Maria Griewing, et al.
Published: (2021-03-01)

Lack of Conventional Acinar Cells in Parotid Salivary Gland of Patient Taking an Anti-PD-L1 Immune Checkpoint Inhibitor
by: Sarah Pringle, et al.
Published: (2020-04-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
by: Kazuhiko Hashimoto, et al.
Published: (2020-07-01)

Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review
by: Chang Liu, et al.
Published: (2021-04-01)

TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma
by: Itay Raphael, et al.
Published: (2021-05-01)

PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research
by: Yu Zhang, et al.
Published: (2021-03-01)

Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity.
by: Angela Y Higgins, et al.
Published: (2021-01-01)

Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
by: Paola Ciciola, et al.
Published: (2020-03-01)

Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing
by: Antonio Lopez-Beltran, et al.
Published: (2021-03-01)

440 Activity and safety of camrelizumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced non-small-cell lung cancer
by: Wei Wang, et al.
Published: (2020-11-01)

Engineering Chimeric Antigen Receptor T-cells Against Immune Checkpoint Inhibitor PD1 and PD-L1 for Treating Pancreatic Cancer
by: Ming-Huei Fan, et al.
Published: (2018)